Sessions

THE POTENTIAL & PROMISE OF ALLOGENEIC
THE CONTINUED RISE & APPLICATION OF AUTOLOGOUS THERAPIES
THE EXPONENTIAL GROWTH OF GENE THERAPY & IT’S FUTURE POTENTIAL

THE POTENTIAL & PROMISE OF ALLOGENEIC

01 Sep 2022
15:30

15:30 – CHAIR INTRODUCTION

Chair: Mark Lowdell, Chief Scientific Officer, INmune Bio

 

15:35 РCASE STUDY: TCR-NK: A NOVEL TREATMENT PARADIGM FOR THE TREATMENT OF SOLID CANCERS 

Speaker: Namir Hassan, CEO, Zelluna

 

15:50 РCASE STUDY: TRANSITION FROM AUTOLOGOUS TO FULLY ALLOGENEIC GAMMA-DELTA T CELL THERAPY 

Speaker: Michael Leek, Executive Chairman & Founder, TC BioPharm

 

16:05 – CASE STUDY: PROGRESS TRENDS & FUTURE DIRECTIONS OF ALLOGENEIC THERAPIES

Speaker: Stefanos Theoharis, Chief Business Officer, Bone Therapeutics S.A

 

16:20 – CASE STUDY: MONITORING ALLOGENEIC CELL MEDICINES IN VIVO – WHAT IS “ENGRAFTMENT” AND IS IT NECESSARY?

Speaker: Mark Lowdell, Chief Scientific Officer, INmune Bio

 

16:35 – Q&A WITH SESSION SPEAKERS

Speakers:

Namir Hassan, CEO, Zelluna

Michael Leek, Executive Chairman & Founder, TC BioPharm

Stefanos Theoharis, Chief Business Officer, Bone Therapeutics S.A

Speakers

Mark Lowdell
CSO/CMO
INmune Bio
Michael Leek
Executive Chairman & Founder
TC Biopharm
Stefanos Theoharis
Chief Business Officer
Bone Therapeutics